Vaccination with the surface proteins MUL_2232 and MUL_3720 of Mycobacterium ulcerans induces antibodies but fails to provide protection against Buruli ulcer by Bolz, Miriam et al.
RESEARCH ARTICLE
Vaccination with the Surface Proteins
MUL_2232 and MUL_3720 ofMycobacterium
ulcerans Induces Antibodies but Fails to
Provide Protection against Buruli Ulcer
Miriam Bolz1,2, Angèle Bénard1,2¤a, Anita M. Dreyer1,2¤b, Sarah Kerber1,2,
Andrea Vettiger1,2, Wulf Oehlmann3, Mahavir Singh3, Malcolm S. Duthie4,
Gerd Pluschke1,2*
1 Swiss Tropical and Public Health Institute, Basel, Switzerland, 2 University of Basel, Basel, Switzerland,
3 Lionex GmbH, Braunschweig, Germany, 4 IDRI, Seattle, Washington, United States of America
¤a Current Address: Wellcome Trust Sanger Institute, Hinxton, United Kingdom
¤b Current Address: LimmaTech Biologics, Schlieren, Switzerland
* gerd.pluschke@unibas.ch
Abstract
Background
Buruli ulcer, caused by infection withMycobacterium ulcerans, is a chronic ulcerative
neglected tropical disease of the skin and subcutaneous tissue that is most prevalent in
West African countries.M. ulcerans produces a cytotoxic macrolide exotoxin called myco-
lactone, which causes extensive necrosis of infected subcutaneous tissue and the develop-
ment of characteristic ulcerative lesions with undermined edges. While cellular immune
responses are expected to play a key role against early intracellular stages ofM. ulcerans in
macrophages, antibody mediated protection might be of major relevance against advanced
stages, where bacilli are predominantly found as extracellular clusters.
Methodology/Principal Findings
To assess whether vaccine induced antibodies against surface antigens ofM. ulcerans can
protect against Buruli ulcer we formulated two surface vaccine candidate antigens,
MUL_2232 and MUL_3720, as recombinant proteins with the synthetic Toll-like receptor 4
agonist glucopyranosyl lipid adjuvant-stable emulsion. The candidate vaccines elicited
strong antibody responses without a strong bias towards a TH1 type cellular response, as
indicated by the IgG2a to IgG1 ratio. Despite the cross-reactivity of the induced antibodies
with the native antigens, no significant protection was observed against progression of an
experimentalM. ulcerans infection in a mouse footpad challenge model.
Conclusions
Even though vaccine-induced antibodies have the potential to opsonise the extracellular
bacilli they do not have a protective effect since infiltrating phagocytes might be killed by
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mycolactone before reaching the bacteria, as indicated by lack of viable infiltrates in the
necrotic infection foci.
Author Summary
Buruli ulcer is a slow progressing ulcerative disease of the skin and subcutaneous tissue
that is most prevalent in West African rural communities.Mycobacterium ulcerans, the
causative agent of the disease, produces a toxin called mycolactone, which is held responsi-
ble for the extensive tissue damage seen in advanced Buruli ulcer lesions. To date, no effec-
tive vaccine against the disease exists and it is unclear to what extent antibodies against cell
surface antigens ofM. ulcerans play a role in protection. To assess whether vaccine
induced antibodies against cell surface proteins can protect against Buruli ulcer, we formu-
lated two surface vaccine candidate antigens, MUL_2232 and MUL_3720, as adjuvanted
recombinant proteins and investigated their protective potential in a mouse model ofM.
ulcerans infection. Despite the induction of strong antibody responses against the surface
molecules and cross-reactivity of the induced antibodies with the antigens in their native
context, we did not observe protection against the disease. While the vaccine-induced anti-
bodies could opsonize the extracellular bacilli, infiltrating phagocytes might be killed early
by mycolactone.
Introduction
Buruli ulcer (BU) is a neglected tropical disease of the skin and subcutaneous tissue reported
from over 30 countries worldwide. BU is most prevalent in West African countries like Cote
d’Ivoire, Cameroon, Benin and Ghana [1,2].Mycobacterium ulcerans, the causative agent of
BU, produces a macrolide exotoxin called mycolactone, which is responsible for extensive
necrosis of infected subcutaneous tissue leading to the development of large ulcerative lesions,
if not treated at an early stage [3]. While extensive surgical removal of the diseased tissue has
been the only treatment approach for a long time, since 2004 the WHO recommends eight
weeks of combination chemotherapy with rifampicin and streptomycin [4]. This change in
treatment strategy has substantially decreased both the amount of surgery required for treat-
ment of extensive skin lesions as well as recurrence rates [5–7]. Nevertheless, BU has remained
a huge socioeconomic burden in endemic regions of Africa. Affected populations are typically
living in rural regions with limited access to health care services and limited financial resources,
frequently resulting in delayed health care seeking and presentations with large ulcerative
lesions, which take long time to heal [8,9].
Sero-epidemiological studies have shown that active BU only develops in some of the people
exposed toM. ulcerans [10,11]. Together with reports on spontaneous healing of BU lesions
[12,13] and the fact that the risk for young adults to develop BU is much smaller than for chil-
dren [14], this observation suggests that development of protective immunity against BU is
possible [15]. However, it is not clear which immune effector functions are important for pro-
tection. Cellular immunity is expected to play a key role in the early intracellular growth phase
ofM. ulcerans in macrophages [16–18]. However, induction of TH1 responses by vaccination
with Bacillus Calmette-Guérin (BCG) or a mycolactone negativeM. ulcerans strain conferred
only transient protection in an experimental mouse infection model [19]. Likewise, BCG vacci-
nation seems to lead to cross-reactive immunity to severe forms of BU in clinical trials [20,21],
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but the BCG mediated induction of cellular response was not able to protect completely from
M. ulcerans disease in either mice or humans [19–21]. In advanced BU lesions, in which clus-
ters of extracellular bacilli dominate, antibodies against surface proteins ofM. ulceransmay be
of major importance for conferring protection [18,22,23]. In order to study this hypothesis,
twoM. ulcerans surface antigens, MUL_2232 and MUL_3720, were chosen in this study as vac-
cine candidate antigens. MUL_2232, the 18 kDa small heat shock protein ofM. ulcerans, is an
immunodominant cell wall associated protein with a homologue found inM. leprae, but not in
M. bovis orM. tuberculosis [10]. MUL_3720 is a 22 kDa molecule with a predicted N-terminal
lectin domain and a C-terminal peptidoglycan-binding domain with a putative role in cell
attachment and cell-cell interaction [24] that is highly expressed on the surface of the bacilli
[25].
Within the framework of a collaborative project (BuruliVac) our goal was to assess whether
vaccine induced antibody responses against surface proteins ofM. ulcerans are protective
against BU. Here we present immunogenicity studies of MUL_2232 and MUL_3720 formu-
lated as adjuvanted recombinant proteins with Alum, Sigma adjuvant (a squalene oil-in-water
emulsion containing Monophosphoryl Lipid A (MPL) and synthetic trehalose dicorynomyco-
late) or EM048 (glucopyranosyl lipid adjuvant-stable emulsion (GLA-SE) adjuvant system
[26,27]). Further, we assessed the potential of the induced immune responses to confer protec-
tion against experimental infection in a murineM. ulcerans infection model.
Material and Methods
Ethical statement
All animal experiments performed were approved by the animal welfare committee of the Can-
ton of Basel (authorization number 2375) and the Canton of Vaud (authorization number
2261) and were conducted in compliance with the Swiss animal protection law (Tierschutzge-
setz, TSchG, 455). Infection experiments withM. ulcerans were conducted under Biosafety-
level-3 conditions at the École polytechnique fédérale de Lausanne (EPFL).
Expression and purification of recombinantM. ulcerans proteins
The potential protein vaccine candidate antigens MUL_2232 (GenBank accession number
4550596) and MUL_3720 (GenBank accession number 4553013) ofM. ulcerans Agy99 were
ordered as codon optimized genes for expression in human cells (GenScript) and received in
pUC57 plasmids. Expression of the antigens as recombinant proteins in E. coli was achieved
with the pET28a expression system (Novagen, modified to contain an ampicillin selection cas-
sette). Briefly, restriction sites required for further cloning were attached by the use of specifi-
cally designed primers for amplification of the codon optimized sequences by polymerase
chain reaction (PCR). Primer sequences for MUL_22232 amplification were 5’-TTCCTTCA
TATGCTGATGAGAACCGACCCTTTTAGA-3’ and 5’-TTCCTTGCGGCCGCTCAAGCCT
CAATCACTTCGGGA. Primer sequences for MUL_3720 amplification were 5’-TTCCTTCA
TATGAGCGATACTCTGACTGAAGGACAG-3’ and 5’-TTCCTTGCGGCCGCGCTCAAG
GAATAGTCAGGACCTCT-3’. PCR products were cut by the restriction enzymes NdeI and
NotI (New England Biolabs) and subsequently ligated into pET28 to attach an N-terminal
6xHis-tag. After propagation of the generated plasmids in Top10 E. coli (Invitrogen), control
restriction and sequencing of the plasmids ensured selection of appropriate clones for expres-
sion of the proteins. Protein expression was induced in E. coli BL21(DE3) strains (Invitrogen)
by addition of 1 mM isopropyl thiogalacoside (Calbiochem) for 4 h at 37°C in lysogeny broth
(LB) medium supplemented with Ampicillin. After screening for high level recombinant
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protein expression by analysis of small induced cultures, larger amounts of recombinant pro-
teins were produced by selected expression clones.
Protein lysates were produced by dilution of the bacterial pellet in PBS, the addition of lyso-
zyme and sonication. After removal of cellular debris by centrifugation, the 6xHis-tagged recom-
binant proteins were purified by nickel-nitrilotriacetic acetic (Ni-NTA) metal-affinity
chromatography. Proteins were eluted with increasing concentrations of imidazole and the integ-
rity and purity of proteins was assessed by SDS-page separation and Coomassie Blue staining (S1
Fig). Final concentrations of the produced recombinant proteins rMUL2232 and rMUL3720
were determined by BCA assay (Pierce) according to the manufacturer’s instructions.
Adjuvant formulations
Oil-in-Water formulated TLR-4 agonist (GLA-SE, EM048) was produced by the Infectious
Disease Research Institute (IDRI) [26,27]. EM048 was mixed with recombinant protein in PBS
to a final concentration of 50 μg/ml EM048 and 200 μg/ml recombinant protein. Sigma adju-
vant system (Sigma) was reconstituted according to the manufacturer’s instructions and com-
bined with recombinant protein to a final concentration of 200 μg/ml recombinant protein.
Imject Alum (Thermo Scientific) was mixed with recombinant protein according to the manu-
facturer’s instructions to a final volume ratio of Imject Alum to immunogen of 1:1 and a final
concentration of 200 μg/ml recombinant protein.
Immunization of mice
Immunogenicity of the described vaccine formulations was studied in 8 week old female
BALB/c mice (Janvier). Groups of five mice were immunized three times by the subcutaneous
(s.c.) route in the scruff of the neck with 100 μl of the adjuvanted proteins in three week inter-
vals. Prior to the first immunization as well as before every new immunization mice were bled
by the tail vein and serum gained by centrifugation of the blood in SST Microtainer tubes (Bec-
ton, Dickinson and Company). An additional blood collection was performed three weeks and
six months after the last immunization.
Enzyme-linked immunosorbent assays (ELISA)
Serum immunoglobulin G (IgG) antibody titers were determined by ELISA on recombinant
protein with all incubation steps performed at room temperature (RT). 10 μg/ml of rMUL2232
or rMUL3720, respectively, were coated on ELISA plates (Maxisorp; Nunc) by incubation over-
night. After blocking with 5% skim milk/PBS for 1 hour, plates were incubated with dilution
series of sera from immunized mice in 0.5% skim milk/PBS for two hours, washed and incu-
bated with alkaline phosphatase-conjugated goat anti-mouse monoclonal antibody (mAb;
Sigma) as secondary antibodies for 1 hour. Plates were washed prior to development with p-
nitrophenyl phosphate (Sigma) as substrate. The optical density (OD) of the reaction product
was measured at 405 nm with a microplate absorbance reader (Sunrise Absorbance Reader;
Tecan). The threshold for endpoint titer determination was defined as the double of the mean
measurements plus the mean standard deviation of a dilution series done without primary anti-
body and a dilution series done with pre-bleed serum. Individual serum dilution series were
approximated with sigmoidal dose-response curves and the reciprocal dilution of the intersec-
tion between the curve and the threshold was defined as individual endpoint titer (GraphPad
Prism software, Graph-Pad Software Inc.).
For the determination of IgG subclasses, ELISA was performed as described above with the
use of subclass specific alkaline phosphate-conjugated secondary antibodies (Southern
Biotech).
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Western blot analysis
According to the manufacturer’s instructions, 10 μg ofM. ulcerans whole cell lysate was loaded
on a prefabricated 4–12% gradient gel (NuPAGE Novex 4–12% Bis-Tris Gel; Invitrogen) with
MES running buffer under reducing conditions. A dry-blotting system (iBlot; Invitrogen) was
used to electrophoretically transfer the separated proteins to nitrocellulose membranes, which
were subsequently blocked in 5% skim milk/PBS over night at 4°C. Membranes were cut into
strips and individually incubated with appropriate dilutions of serum of immunized mice in
1% skim milk/0.05% Tween20 / PBS for 1 hour at RT. After several washing steps in 1% skim
milk/0.05% Tween20/PBS, a HRP-conjugated goat anti-mouse IgG γ-chain mAb (Southern
Biotech) was used as secondary antibody and incubated for 1 hour at RT. Excess antibody and
skim milk residuals were washed away with PBS and blots were then developed using ECL
Western blotting detection reagents (ECLWestern blotting Substrate; Pierce).
For the determination of the Western blot endpoint titers, individual dilution series of sera
were processed as described above. Development of the entire set of strips by the ECL system
was done on one single film. Development time was chosen as the shortest time needed for
detecting a specific signal in at least one strip for every serum dilution, e.g. lowest dilution, and
for every dilution series of individual sera at least one strip with no specific signal, e.g. highest
dilution. Western blot endpoint titers were defined as the reciprocal value of the last dilution
that yielded a specific band in Western blotting on the film.
Immunofluorescence assays on paraffin embeddedM. ulcerans
Immunofluorescence assays with sera of immunized mice on paraffin embeddedM. ulcerans
bacteria were performed as previously described [25]. Briefly, AfricanM. ulcerans isolates were
embedded into paraffin, cut into 3 μm thin sections and mounted on Superforst Plus glass
slides (Thermo Scientific). Sections were then deparaffinised, rehydrated and pre-treated with
1mM EDTA buffer pH = 8 for epitope retrieval as described for tissue sections in immunohis-
tochemistry [28]. Unspecific binding was prevented by incubation of the bacteria in 1.5% goat
serum in PBS for 1 hour at RT. Appropriately diluted mouse mAbs specific for MUL_2232 and
MUL_3720 were used as primary antibodies. Detection of the specific binding of primary anti-
bodies was done with an Alexa488 labelled secondary goat anti-mouse total IgG (H+L) anti-
bodies (Life Technologies). Image acquisition was performed on a confocal laser microscope
(Carl Zeiss, Axiovert 200M).
Active immune protection experiments in mice
Active immune protection experiments were conducted with groups of eight female 8 weeks
old BALB/c mice. Mice were immunized twice s.c. in the scruff of the neck with 100 μl of the
adjuvanted proteins in three week intervals. Three weeks after the second immunization and
prior to infection withM. ulcerans, mice were bled by the tail vein and successful immunization
was verified by testing the sera for specific antibodies in ELISA and Western blotting as
described above. AllM. ulcerans infection experiments were conducted under BSL-3
conditions.
TheM. ulcerans strain S1013 used for the experimental infection of mice was isolated in
2010 from the ulcerative lesion of a Cameroonian BU patient [29]. Bacteria were cultivated in
BacT/ALERT medium (Biomerieux) for six weeks, recovered by centrifugation and diluted in
sterile PBS to 125 mg/ml wet weight. Mice were infected with 1.5 x 106 (high dose) or 1.5 x 105
(low dose) bacteria in PBS into the left hind foot pad three weeks after the last immunization.
The course of the infection was followed by weekly measurements of the foot pad thickness
with a caliper. At days 63 (high dose) and 87 (low dose) after experimental infection, mice were
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euthanised, blood samples harvested through cardiac puncture and foot pads aseptically
removed for enumeration ofM. ulcerans bacteria or histopathology. Mouse foot pads desig-
nated for enumeration ofM. ulcerans bacteria were dipped in 70% ethanol, dried under the
laminar flow, cut into four pieces with a scalpel and transferred to reinforced hard tissue grind-
ing tubes (MK28-R, Precellys) containing 750 μl of BacT/ALERT medium. Tissue homogeniza-
tion was performed with a Precellys 24-Dual tissue homogenizer (3 x 20 s at 5000 rpm with 30
s break), the lysate was transferred to a clean tube and the lysis tube still containing tissue resid-
uals refilled with additional 750 μl of BacT/ALERT medium. The remains were homogenized a
second time as described above and the individual two lysates were pooled [30].
DNA from 100 μl of a 1:50 dilution of the foot pad lysate in PBS was extracted as described
by Lavender and Fyfe [31]. Extracted DNA was then analysed for insertion sequence (IS) 2404
by quantitative (q) PCR as previously described [31]. For graphic representation of the results,
cycle threshold (Ct) values were converted into genome copy numbers per foot pad by applying
a standard curve established for IS2404 by Fyfe et al. [32].
Histopathology
Mouse foot pads designated for histopathological analysis were removed above the ankle and
immediately transferred to 10% neutral-buffered formalin solution (approx. 4% formaldehyde,
Sigma) for fixation during 24 hours at room temperature. Subsequently, the foot pads were
decalcified in 0.6 M EDTA and 0.25 M citric acid for 12 days at 37°C and transferred to 70%
ethanol for storage and transport. Foot pad samples were dehydrated and embedded
into paraffin. 5 μm thin sections were cut, deparaffinised, rehydrated, and stained with
Haematoxylin/Eosin (HE, Sigma, J.T. Baker) or Ziehl-Neelsen/Methylene blue (ZN, Sigma)
according to WHO standard protocols [33]. Stained sections were mounted with Eukitt
mounting medium (Fluka). Pictures were taken with a Leica DM2500B microscope or with an
Aperio scanner.
Results
GLA-SE adjuvanted recombinantM. ulcerans protein formulations
elicited specific antibody responses
The twoM. ulcerans vaccine candidate antigens MUL_2232 and MUL_3720 were expressed as
6xHis-tagged recombinant proteins in E. coli and purified via a Ni-NTA column (S1 Fig). Mice
were immunized three times with either 20 μg of MUL_2232 or MUL_3720 formulated with
the human-compatible GLA-SE adjuvant EM048. Alum and Sigma adjuvant were used as con-
trol adjuvants. ELISA with mouse sera on the respective recombinant proteins showed that all
formulations elicited robust antigen specific serum IgG responses (Fig 1) dominated by IgG1
and only a minor proportion of IgG3 (Fig 2A1 and 2B1).
While rMUL2232-specific IgG2a to IgG1 ratios showed no significant differences among
the different formulations tested (Fig 2A2), IgG2a to IgG1 ratio was significantly higher when
mice were immunized with rMUL3720 EM048 adjuvanted candidate vaccine than with the
two other formulations (Fig 2B2).
Western blotting analyses of sera againstM. ulcerans lysates showed specific bands of the
expected molecular weight of MUL2232 and MUL3720 (Fig 3A, S2A Fig). Sera of immunized
mice also recognizedM. ulcerans bacteria in an indirect immunofluorescence assay (IFA) per-
formed on paraffin embeddedM. ulcerans bacteria (Fig 3B, S2B Fig). For both target antigens
the previously demonstrated surface localization [25] was confirmed. Six months after the last
immunization, antibody responses in all groups of immunized mice had dropped significantly.
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However, specific antibody titres were still higher than in the pre-immune sera and sufficient
to elicit signals in Western blotting analyses (Fig 2A3 and 2B3).
Assessment of protectivity of the vaccine induced antibody responses in
an experimentalM. ulcerans infection mouse model
Given that antigens formulated with the human-compatible EM048 elicited higher total IgG
responses after two injections and with similar IgG1, but higher IgG2a, IgG2b, IgG3 antibody
levels compared to formulation with Alum, we determined the protective potential of these
vaccine formulations in an experimentalM. ulcerans infection mouse model. Because the
increase of total IgG titers after a third immunization was not significant (Fig 1), groups of
Fig 1. Immunogenicity of recombinant protein/EM048 formulation in comparison to commercially
available adjuvants for mice.Groups of five BALB/c mice were immunized three times in three week
intervals with 20 μg of rMUL2232 (A) or rMUL3720 (B) in PBS or formulated with Alum, Sigma Adjuvant or
EM048. Serum three weeks after every immunization (I1, I2 and I3) was analysed in ELISA on the respective
recombinant protein. Depicted are individual endpoint IgG titers as determined in one single ELISA, the mean
(line) ± standard deviation. Values that are zero are not depicted but were included for statistical analysis.
Overall statistical significance was calculated by Kruskal-Wallis test per immunization time point (A: PI1 =
0.0018, PI2 = 0.0372 and PI3 = ns.; B: PI1 = 0.0095, PI2 = 0.0011, PI3 = 0.0041.). Individual statistical
differences between groups were assessed by the Dunn procedure and are depicted if detected (* p 0.05;
** p 0.01).
doi:10.1371/journal.pntd.0004431.g001
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Fig 2. Assessment of Immunoglobulin G subclasses and the longevity of antibody responses induced by immunization. Immunoglobulin G (IgG)
subclasses were determined in serum collected three weeks after the third immunization with rMUL2232 (A1) and the indicated adjuvant or rMUL3720 (B1)
and the indicated adjuvant. ELISA on recombinant protein was performed with secondary antibodies specific for four IgG subclasses: IgG1 (black), IgG2a
Lack of Antibody Mediated Protection against BU
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eight mice were immunized twice with rMUL3720/EM048. Three weeks after the second
immunization mice were infected into the left hind foot pad with an inoculum of 1.5 x 106
(high dose) or 1.5 x 105 (low dose) ofM. ulcerans bacilli. The course of the infection was fol-
lowed by weekly measurements of the foot pad thickness with a caliper. Mice in all groups
(dark grey), IgG2b (light grey), IgG3 (very light grey). Depicted are the mean individual endpoint IgG titers determined in one single ELISA (bar), and the
standard deviation (error bar). Overall statistical significance was calculated by Kruskal-Wallis test (A1: PIgG1 = 0.0265., PIgG2a = 0.0205, PIgG2b = ns., PIgG3 =
0.0276; B1: PIgG1 = 0.0034., PIgG2a = 0.0017, PIgG2b = 0.0048, PIgG3 = ns.). Individual statistical differences between groups were assessed by the Dunn
procedure and are depicted if detected (* p 0.05; ** p 0.01). The ratio of IgG2a to IgG1 was determined for individual animals accordingly (A2 and B2).
Depicted are the individual values, the mean IgG2a to IgG1 ratio (bar) and the standard deviation (error bar). Overall statistical significance was calculated by
Kruskal-Wallis test (A2: P = ns.; B2: P = 0.0024). Individual statistical differences between groups were assessed by the Dunn procedure and are depicted if
detected (** p 0.01). Total IgG titers in individual immunized mice three weeks (t1) and six months (t2) after the third immunization were compared by
Western blotting onM. ulcerans lysate. Depicted are individual Western blot endpoint titers and the median per group (line) for rMUL2232 immunized animals
(A3) and rMUL3720 immunized animals (B3). Statistical significance was assessed by Mann-Whitney test and is depicted if detected (* p 0.05;
** p 0.01).
doi:10.1371/journal.pntd.0004431.g002
Fig 3. Cross reactivity of the immune sera withM. ulcerans. (A) Groups of five BALB/c mice (m1 –m5) were immunized three times in three week
intervals with 20 μg of rMUL2232 formulated with Alum, Sigma Adjuvant or EM048. Serum three weeks after every immunization (I1, I2 and I3) was analysed
byWestern blotting onM. ulcerans lysate. Monoclonal anti-MUL_2232 antibody (mAb) served as positive control, pre-bleed (pb) serum or no primary
antibody (nc) as negative controls. (B) Sera from three weeks after the third immunization with rMUL2232 and indicated adjuvant were used for indirect
immunofluorescence staining on paraffin embeddedM. ulcerans bacteria with an Alexa488 labelled secondary antibody. Pre-bleed serum did not stain the
bacteria. Sera of immunized mice (a mix of sera from five individual mice per group) did reveal surface staining similar to the staining achieved with anti-
MUL_2232 monoclonal antibody (mAb).
doi:10.1371/journal.pntd.0004431.g003
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infected with the high dose of bacteria showed first signs of inflammation and foot pad swelling
seven weeks after infection (Fig 4A). Swelling gradually increased over time, until mice had to
be euthanised at day 63 and the bacterial load was determined by qPCR (Fig 4B). Compared to
the amount ofM. ulcerans DNA that was contained in the inoculum, a roughly 250 times
increase had occurred both in immunized and control animals during the 63 days of infection
(Fig 4B).
Histopathological analysis of representative foot pads revealed the presence of oedema (Fig
5B1 and 5B4) and slight infiltration at the site of infection (Fig 5B6) as well as at the heel of the
foot pad (Fig 5B2). Acid fast bacilli (AFB) were found at all sites where infiltration occurred
(Fig 5B3, 5B5 and 5B7).
In mice infected with the low dose inoculum, foot pad swelling started seven to eight weeks
after infection (Fig 4A) and the increase inM. ulcerans DNA content was about 9500 fold in 87
days. Also with the lower challenge dose no difference in bacterial load was observed between
immunized and control immunized animals (Fig 4B). Large clumps of AFB were found in all
infected foot pads irrespective of the immunization status of the mice (Fig 5C1, 5C2 and 5D1.
AFB occurred in clumps (Fig 5C2), organized within filamentous structures principally located
in oedematous tissue (Fig 5C3 and 5D3) and in close contact with infiltrating cells (Fig 5D2).
Similarly, rMUL2232/EM048 did not induce any protective effect (S3 Fig).
Fig 4. Evaluation of the protective potential of immunization with rMUL3720/EM048 formulation in aM. ulcerans infection mousemodel.Groups of
eight BALB/c mice were immunized twice with 20 μg of rMUL3720/EM048 or PBS alone as infection control. Three weeks after the last immunization mice
were challenged with a high dose or a low dose ofM. ulcerans (inoculum) into the left hind foot pad. Infection was followed by measuring foot pad thickness
with a caliper (A) until mice were euthanized at day 63 after infection (high dose, H1) or at day 87 after infection (low dose, H2). Depicted is the mean foot pad
thickness (diamond/circle) ± standard deviation of the differently immunized groups. (B) Bacterial load in infected foot pads was determined by qPCR for six
mice per group. Depicted are individual measurements as genome copies per foot pad, the mean (line) ± standard deviation.
doi:10.1371/journal.pntd.0004431.g004
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M. ulcerans infection failed to boost immunization-induced antibody
responses
Antibody titers in immunized mice before infection (S4 Fig) and after 63 days of infection were
directly compared to elucidate whether the immunization-induced antibody responses were
increased by exposure to the target antigens in the native context of the infecting bacilli. No
booster effect was observed after infection with the high dose inoculum ofM. ulcerans (Fig 6A1
and 6A2). On the contrary, both ELISA and Western blotting analyses demonstrated a signifi-
cant drop in specific antibody titres after infection (Fig 6B), which represents most probably a
natural decrease over time. Furthermore, neither non-immunized nor control-immunized ani-
mals raised a specific antibody response against rMUL2232 (Fig 6A1) or rMUL3720 (Fig 6A2)
andWestern blotting analyses of these control sera revealed a profound lack of anyM. ulcerans
specific antibody responses in the course of infection (Fig 6B).
Fig 5. Histopathological evaluation of mouse footpads followingM. ulcerans infection. Histological
sections of foot pads fromM. ulcerans-infected mice were stained with Haematoxylin/Eosin (A, B1—B7) or
Ziehl-Neelsen/Methylene blue (ZN) (C1—C4, D1—D4). Mice challenged with a high dose ofM. ulcerans
developed typical signs of infection in the mouse foot pad model until day 63 after infection. Compared to a
control foot pad (A) the infected foot pad of a representative immunized mouse (B1) showed necrosis and
infiltration interspersed with AFB at the ankle (B2, B3) as well as at the base of the foot (B6, B7). Oedema was
marked on top of the foot pad (B4) where bacteria were also found (B5). Immunized mice (C1) as well as
control mice (D1) challenged with a lower dose ofM. ulcerans developed strong infection foci until day 87
after infection. AFB appeared as big, dense clumps (C2) or in close association with infiltrating cells (D2)
towards the heel of the infected foot pads as well as in the middle of the foot (C1, D1). AFB were also present
in oedematous tissue in the upper half of the foot (D3) and appeared in filamentous organization (C3).
doi:10.1371/journal.pntd.0004431.g005
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Fig 6. Evaluation of the booster effect ofM. ulcerans infection on the pre-existing antibody response
in rMUL3720/EM048 immunized and subsequently infectedmice. (A1) Serum of six BALB/c mice
immunized with rMUL2232/EM048 prior to infection (before infection) withM. ulcerans was compared to
serum of the same animals after 42 days of infection (after infection) in ELISA on rMUL2232. Control
immunized animals had received PBS/EM048 or only PBS prior to infection. Depicted are individual endpoint
IgG titers as determined in one single ELISA, the group mean (line) ± standard deviation. Statistical
significance was calculated by the Student’s t- test (** p 0.01). (A2) Serum of eight BALB/c mice
immunized with rMUL3720/EM048 prior to infection withM. ulcerans was compared to serum of the same
Lack of Antibody Mediated Protection against BU
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Discussion
Currently, there is no highly effective vaccine against the mycobacterial diseases tuberculosis,
leprosy and BU available. BCG was originally developed as a vaccine against tuberculosis, but,
dependent on the study site, a protective efficacy ranging from 20% to 90% was also observed
against leprosy [34,35]. Similarly, BCG was found to offer a short-lasting protection of 47%
against BU in a controlled clinical trial in Uganda [20], reconfirming results of a previous
smaller trial [36]. However, case-control studies have failed to provide evidence of a lasting
protective effect of routine BCG vaccination against BU [37–39]. Yet inM. ulceransmouse
infection models any other vaccine candidate has so far outperformed the effectiveness of BCG
[18].
As a partner in the collaborative research project BuruliVac, we seeked to assess the poten-
tial to develop a protein based subunit vaccine against BU. Here we report results obtained
with two cell surface exposedM. ulcerans proteins formulated with the adjuvant EM048. In
spite of the development of robust humoral immune responses, none of the vaccination formu-
lations tested conferred protection in the experimentalM. ulceransmouse foot pad infection
model.
Choosing potential protective antigens for the inclusion into a protein subunit vaccine
against BU was difficult, since the nature of protective immune responses against the disease is
unclear. Given the mainly extracellular location ofM. ulcerans in advanced lesions, the choice
of surface exposed proteins seemed most attractive. Additionally,M. ulcerans specific proteins
were of preference, because it was already observed that proteins from the closely related path-
ogensM. bovis andM. leprae were not very effective in conferring cross-protectivity, despite
high sequence homology [40–42]. We have chosen MUL_2232 for its known surface localiza-
tion, its strong immunogenicity and its missing homolog inM. tuberculosis [10]. The second
candidate, MUL_3720, was identified in a screen for potential diagnostic antigens conducted in
our laboratory [24]. Homologs of MUL_3720 are absent in other mycobacterial pathogens
prevalent in BU endemic areas. Furthermore, it is highly expressed and most importantly it is
located on the surface ofM. ulcerans [25].
In light of current literature available on protective immunity to BU we have chosen to for-
mulate the selected antigens with the human compatible adjuvant GLA-SE. GLA is a synthetic
Toll-like receptor 4 agonist, that has been demonstrated to confer potent adjuvant activity for
various antigens [26,43–45] when formulated with a squalene based oil-in-water stable emul-
sion (SE). While SE is an adjuvant on its own, the addition of GLA biases the induced cell
mediated immunity (CMI) toward a TH1 type immune response, an observation made for
several antigens tested so far [43,46]. However, formulations of the recombinant proteins
rMUL2232 and rMUL3720 with EM048, the specific GLA-SE adjuvant used in this study, did
not lead to such a clear shift of CMI towards TH1, as we have assessed by the IgG2a/IgG1 ratios.
Yet compared to Alum, which is still the adjuvant most commonly used in human vaccines,
EM048 induced significantly higher antibody titres with both recombinant proteins investi-
gated. All mice immunized with adjuvanted recombinant protein vaccine-candidates and later
challenged withM. ulcerans had mounted strong specific antibody responses, which were
animals 63 days after infection withM. ulcerans bacteria in ELISA on rMUL3720. Control immunized animals
(control) had only received PBS prior to infection. Depicted are individual endpoint IgG titers as determined in
one single ELISA, the mean (line) ± standard deviation. Statistical significance was calculated by the
Student’s t- test (**** p 0.0001). (B) Serum of six BALB/c mice (m1 –m6) immunized with rMUL3720/
EM048 prior to infection withM. ulcerans (a) was compared to serum of the same animals after 42 days of
infection (b) by Western blotting onM. ulcerans whole cell lysate. Monoclonal anti-MUL_3720 antibody (mAb)
served as positive control, pre-bleed (pb) serum or no primary antibody (nc) as negative controls.
doi:10.1371/journal.pntd.0004431.g006
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cross-reactive with the antigens in the native context on the bacterial cell surface. Nevertheless,
these mice were not protected from disease. Opsonisation of the bacteria by the immunization-
induced antibodies may not lead to protection, since the clusters of the extracellularM. ulcer-
ans found in advanced BU lesions are imbedded in necrotic tissue. Infiltrating macrophages
are therefore not able to reach the bacteria, since infiltrating cells seem to be killed by mycolac-
tone before reaching the infection foci. On the other hand, it is not completely ruled out that
antibodies against other target structures may be protective. Neutralizing antibodies against
the poorly immunogenic macrolide toxin mycolactone for example could potentially confer
protection against disease. The fact that the response of immunized mice was not boosted
upon progressive infection withM. ulcerans could hint to another obstacle for vaccine develop-
ment against BU. The apparent general lack of antibody responses in non-immunized chal-
lenged control mice that was observed by us and others [23] is surprising, and requires further
investigation. A number of studies have reported systemic T-cell anergy in patients with BU,
but development of antibody responses againstM. ulcerans was detected in a majority of
patients [10,47–49].
In the framework of this study we have developed methods to evaluate the protective capac-
ity of candidate vaccines in theM. ulceransmouse footpad infection model. The fact that we
did not see protection in immunized animals could have many explanations; including insuffi-
cient bias towards a TH1 type of CMI. Most likely immunization with only one antigen is gen-
erally not sufficient for protection against disease. Considering that vaccination with a
mycolactone deficient mutant strain ofM. ulcerans did not lead to full protection in the mouse
model [19], the development of a multivalent subunit vaccine may be the right strategy to
pursue.
Supporting Information
S1 Fig. TwoM. ulcerans candidate vaccine antigens expressed as recombinant proteins in
E. coli. Indicated amounts of rMUL2232 (A) or rMUL3720 (B) were resolved on SDS-page and
stained with Coomassie blue.
(PDF)
S2 Fig. Cross reactivity of immune sera withM. ulcerans. (A) Groups of five BALB/c mice
(m1 –m5) were immunized three times in three week intervals with 20 μg of rMUL3720 formu-
lated with Alum, Sigma Adjuvant or EM048. Serum after every immunization (I1, I2 and I3)
was analysed by Western blotting onM. ulcerans lysate. Monoclonal anti-MUL_3720 antibody
(mAb) served as positive control, pre-bleed (pb) serum or no primary antibody (nc) as negative
controls. (B) Sera from three weeks after the third immunization with rMUL3720 and indi-
cated adjuvant were used for indirect immunofluorescence staining on paraffin embeddedM.
ulcerans bacteria with an Alexa488 labelled secondary antibody. Pre-bleed serum did not stain
the bacteria. Sera of immunized mice (a mix of sera from five individual mice per group) did
reveal surface staining similar to the staining achieved with anti-MUL_3720 monoclonal anti-
body (mAb).
(PDF)
S3 Fig. Evaluation of the protective potential of immunization with rMUL2232/EM048 for-
mulation in aM. ulcerans infection mouse model. Groups of six BALB/c mice were immu-
nized twice with 20 μg of rMUL2232/EM048, PBS/EM048 or PBS alone as infection control.
Three weeks after the last immunization mice were challenged withM. ulcerans (inoculum)
into the left hind foot pad. Infection was followed by measuring foot pad thickness with a cali-
per (A1) until mice were euthanized at day 42 after infection. Depicted is the mean foot pad
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thickness (diamond/dot) ± standard deviation of the differently immunized groups. (A2) Bac-
terial load in infected foot pads was determined by qPCR for five mice per group. Depicted are
individual measurements as genome copies per foot pad, the mean (line) ± standard deviation.
(PDF)
S4 Fig. Reactivity of immune sera onM. ulcerans lysate. Groups of eight BALB/c mice were
immunized twice with 20 μg of rMUL3720/EM048 or PBS only as infection control. Serum
prior to infection withM. ulcerans was analysed by Western blotting onM.ulcerans lysate.
Monoclonal anti-MUL_3720 antibody (mAb) served as positive control, pre-bleed (pb) serum
or no primary antibody (neg) as negative controls. C1 and C2 each represent a mix of sera of
eight mice immunized with PBS only.
(PDF)
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